


# Academic Pharma

Prof. Dr. T. van Gelder (Teun)  
Internist – clinical pharmacologist

Leiden University Medical Center  
University Leiden





# Disclosures

Name:

Teun van Gelder, MD, Leiden Univ Medical Center, Netherlands

Commercial Interests & Nature of Relationships:

- Roche, Astellas, Aurinia, CSL Behring, Chiesi, Roche Diagnostics, Thermo Fisher: Consultant/Speaker received honoraria
- Chiesi and Astellas: Research Grant Support, study on transplant related diseases
- I am an employee of LUMC





# Discovery and development:

Basic science:

- New targets
- New compounds

Translational research

Clinical studies:

- Phase 1
- Phase 2
- Phase 3

Registration



**Vereniging  
Innovatieve  
Geneesmiddelen**






# The Leiden Landscape



**Landscape for drug development:**  
Leiden Institute for Chemistry, LACDR , CHDR, LUMC,  
Leiden BioScience Park, TNO



# Team work





University Leiden Research Program 'Translational Drug Discovery & Development'

Matched funding from strategic fund LUMC:

Academic Pharma 2.0: Innovative drugs from bench to bed-side.

LUMC STRATEGIE 2018-2023

**GRENSVER  
LEGGEND  
> BETER  
WORDEN**



## Perspective of “the” academic researcher:

- Focus on science, innovation, top-publications.
- Focus on own domain, not on development plan or pipeline.
- After finishing project: risk that finding ends up on a shelf.
- Missed opportunities.
- Academic freedom.
- Less awareness for intellectual property or valorisation.
- Perception that fundamental research is a higher goal than bringing compound to patient



# Aiming high

Registration of drugs:


Complex.

For academia the same rules apply.





# The valley of death





Leiden Early Drug Discovery & Development

https://www.universiteitleiden.nl/en/science/led3

Leiden University | Students | Staff members | Organisational structure | Library

Universiteit Leiden

Search for subject or person

All categories

Nederlands English

Home > Faculty of Science > Leiden Early Drug Discovery & Development

LED3

Leiden Early Drug Discovery and Development

Leiden Early Drug Discovery & Development

Science

Leiden Early Drug Discovery & Development

Despite recent advances in medicine, many devastating disorders like cancer and cardiovascular, neurodegenerative and infectious diseases still lack effective treatments. In order to address this challenge, we, as scientists from Leiden University, joined hands in the LED3 network. LED3, for Leiden Early Drug Discovery & Development, is a partnership between the Institute of Biology Leiden (IBL), Leiden Institute of Chemistry (LIC) and the Leiden Academic Centre for Drug Research (LACDR).

Together, we pursue the discovery of novel drug targets, molecules, and concepts for drug discovery, so that more effective and safer treatments can be developed in the future. Our research themes are centered around the early drug discovery pipeline. For each pipeline stage we will show how the combined expertise and facilities of the LED3 network leads to enhanced drug discovery, but also how partnerships with industry can take us even further.

Fundamental knowledge enhances drug discovery

The overarching LED3 vision is that if we understand more about the

11:25  
08-11-2021



## Support from Academic Pharma:

- Awareness of (im)possibility of protecting intellectual property
- Publication Y/N
- Non Disclosure Agreements
- Project based approach: start with the end goal.
- Awareness of impact of regulatory issues
- Possibility scientific advice
- Funding



## Academic Pharma:

- No “me too” drugs
- No generic production
- Unmet clinical need
- Rare diseases, compounds without patent are welcome
- New Chemical Entities, as well as repurposing
- Protect magisterial preparations against price hikes



# Academic Pharma

Not our ambition to be a big drug factory

Licencing agreements



# National Farmaceutic Knowledge Center (NFKC)

**Stichting Nationaal Farmaceutisch Kennis-, Ontwikkel- en Opleidingscentrum.  
(opgericht door LUMC, TNO, LBSP op 29 juni 2020)**

## **Goals:**

- Support the development of innovative drugs in academia
- Develop and offer expertise in drug development to academic researchers
- Teach and train students, PharmDs, MDs, MScs... in drug discovery and development



# FAST





# National expertise center





## Conclusions & Discussions

- Academic Pharma has been put on the map.
- Complementary to (big) pharma.
- Crossing the valley of death.
- Develop expertise, bundle forces, support academia.
- Local versus national.